150 related articles for article (PubMed ID: 38589857)
1. Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis.
Cirillo A; Marinelli D; Romeo U; Messineo D; De Felice F; De Vincentiis M; Valentini V; Mezi S; Valentini F; Vivona L; Chiavassa A; Cerbelli B; Santini D; Bossi P; Polimeni A; Marchetti P; Botticelli A
BMC Cancer; 2024 Apr; 24(1):430. PubMed ID: 38589857
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Hong RL; González Mendoza R; Roy A; Zhang Y; Gumuscu B; Cheng JD; Jin F; Rischin D;
Lancet; 2019 Nov; 394(10212):1915-1928. PubMed ID: 31679945
[TBL] [Abstract][Full Text] [Related]
3. First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048.
Takahashi S; Oridate N; Tanaka K; Shimizu Y; Fujimoto Y; Matsumoto K; Yokota T; Yamazaki T; Takahashi M; Ueda T; Hanai N; Yamaguchi H; Hara H; Yoshizaki T; Yasumatsu R; Nakayama M; Shiga K; Fujii T; Mitsugi K; Takahashi K; Nohata N; Gumuscu B; Swaby RF; Tahara M
Int J Clin Oncol; 2022 Dec; 27(12):1805-1817. PubMed ID: 36264378
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score.
Burtness B; Rischin D; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Brana I; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesia R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Ge J; Swaby RF; Gumuscu B; Harrington K
J Clin Oncol; 2022 Jul; 40(21):2321-2332. PubMed ID: 35333599
[TBL] [Abstract][Full Text] [Related]
5. The UK Divide: Does Having a Pembrolizumab-Chemotherapy Option in Head and Neck Cancer Matter? Real-world Experience of First-line Palliative Pembrolizumab Monotherapy and Pembrolizumab-Chemotherapy Combination in Scotland.
Thapa A; Cowell A; Peters A; Noble DJ; James A; Lamb C; Grose D; Vohra S; Schipani S; Mactier K; Mackenzie J; Srinivasan D; Laws K; Moleron R; Niblock P; Soh FY; Paterson C; Wilson C
Clin Oncol (R Coll Radiol); 2024 May; 36(5):287-299. PubMed ID: 38395634
[TBL] [Abstract][Full Text] [Related]
6. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers predictive of response to pembrolizumab in head and neck cancer.
Pfister DG; Haddad RI; Worden FP; Weiss J; Mehra R; Chow LQM; Liu SV; Kang H; Saba NF; Wirth LJ; Sukari A; Massarelli E; Ayers M; Albright A; Webber AL; Mogg R; Lunceford J; Huang L; Cristescu R; Cheng J; Seiwert TY; Bauml JM
Cancer Med; 2023 Mar; 12(6):6603-6614. PubMed ID: 36479637
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States.
Borse RH; Ramakrishnan K; Gandhi J; Dhankhar P; Chirovsky D
J Med Econ; 2022; 25(1):954-965. PubMed ID: 35765888
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab with or without chemotherapy versus cetuximab plus chemotherapy to treat recurrent or metastatic head and neck squamous cell carcinoma: An updated KEYNOTE-048 based cost-effectiveness analysis.
She L; Tian K; Han J; Zuo W; Wang Z; Zhang N
Oral Oncol; 2022 Jun; 129():105871. PubMed ID: 35483156
[TBL] [Abstract][Full Text] [Related]
10. Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.
Cortellini A; Cannita K; Tiseo M; Cortinovis DL; Aerts JGJV; Baldessari C; Giusti R; Ferrara MG; D'Argento E; Grossi F; Guida A; Berardi R; Morabito A; Genova C; Antonuzzo L; Mazzoni F; De Toma A; Signorelli D; Gelibter A; Targato G; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Mansueto G; Zoratto F; Filetti M; Bracarda S; Citarella F; Russano M; Cantini L; Nigro O; Buti S; Minuti G; Landi L; Ricciardi S; Migliorino MR; Natalizio S; Simona C; De Filippis M; Metro G; Adamo V; Russo A; Spinelli GP; Di Maio M; Banna GL; Friedlaender A; Addeo A; Pinato DJ; Ficorella C; Porzio G
Eur J Cancer; 2021 May; 148():24-35. PubMed ID: 33721704
[TBL] [Abstract][Full Text] [Related]
11. Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer.
Emancipator K; Huang L; Aurora-Garg D; Bal T; Cohen EEW; Harrington K; Soulières D; Le Tourneau C; Licitra L; Burtness B; Swaby R
Mod Pathol; 2021 Mar; 34(3):532-541. PubMed ID: 33239737
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001).
Tamiya M; Tamiya A; Hosoya K; Taniguchi Y; Yokoyama T; Fukuda Y; Hirano K; Matsumoto H; Kominami R; Suzuki H; Hirashima T; Uchida J; Morita M; Kanazu M; Sawa N; Kinoshita Y; Hara S; Kumagai T; Fujimoto D
Invest New Drugs; 2019 Dec; 37(6):1266-1273. PubMed ID: 31392549
[TBL] [Abstract][Full Text] [Related]
13. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma.
Haddad RI; Seiwert TY; Chow LQM; Gupta S; Weiss J; Gluck I; Eder JP; Burtness B; Tahara M; Keam B; Kang H; Muro K; Albright A; Mogg R; Ayers M; Huang L; Lunceford J; Cristescu R; Cheng J; Mehra R
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35217573
[TBL] [Abstract][Full Text] [Related]
14. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
Chow LQM; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder JP; Burtness B; Lee SH; Keam B; Kang H; Muro K; Weiss J; Geva R; Lin CC; Chung HC; Meister A; Dolled-Filhart M; Pathiraja K; Cheng JD; Seiwert TY
J Clin Oncol; 2016 Nov; 34(32):3838-3845. PubMed ID: 27646946
[TBL] [Abstract][Full Text] [Related]
15. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Cortellini A; Tiseo M; Banna GL; Cappuzzo F; Aerts JGJV; Barbieri F; Giusti R; Bria E; Cortinovis D; Grossi F; Migliorino MR; Galetta D; Passiglia F; Santini D; Berardi R; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Tuzi A; Gelibter A; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Mansueto G; Zoratto F; Santoni M; Tudini M; Rijavec E; Filetti M; Catino A; Pizzutilo P; Sala L; Citarella F; Marco R; Torniai M; Cantini L; Targato G; Sforza V; Nigro O; Ferrara MG; D'Argento E; Buti S; Bordi P; Antonuzzo L; Scodes S; Landi L; Guaitoli G; Baldessari C; Della Gravara L; Dal Bello MG; Belderbos RA; Bironzo P; Carnio S; Ricciardi S; Grieco A; De Toma A; Proto C; Friedlaender A; Cantale O; Ricciuti B; Addeo A; Metro G; Ficorella C; Porzio G
Cancer Immunol Immunother; 2020 Nov; 69(11):2209-2221. PubMed ID: 32474768
[TBL] [Abstract][Full Text] [Related]
17. The association between body mass index and efficacy of pembrolizumab as second-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Zhang X; Rui M; Lin C; Li Z; Wei D; Han R; Ju H; Ren G
Cancer Med; 2023 Feb; 12(3):2702-2712. PubMed ID: 35975731
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.
Harrington KJ; Burtness B; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Brana I; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesia R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Lin J; Gumuscu B; Swaby RF; Rischin D
J Clin Oncol; 2023 Feb; 41(4):790-802. PubMed ID: 36219809
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Sun JM; Shen L; Shah MA; Enzinger P; Adenis A; Doi T; Kojima T; Metges JP; Li Z; Kim SB; Cho BC; Mansoor W; Li SH; Sunpaweravong P; Maqueda MA; Goekkurt E; Hara H; Antunes L; Fountzilas C; Tsuji A; Oliden VC; Liu Q; Shah S; Bhagia P; Kato K;
Lancet; 2021 Aug; 398(10302):759-771. PubMed ID: 34454674
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
Poulose JV; Kainickal CT
World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
